Pulmonary hypertensive disorders generally result in a progressively worsening course associated with substantial morbidity and mortality. Nifedipine therapy may provide an effective solution to attenuate the disease state.
To assess the magnitude and consistency of the effect of nifedipine on reducing pulmonary artery pressure in patients with pulmonary hypertensive disorders.
A meta-analysis of 8 trials of nifedipine therapy.
Clinical trials were identified by a computerized literature search of MEDLINE and by an assessment of bibliographies of retrieved studies. Trials were selected if they measured the change in pulmonary artery pressures in their subjects after weeks to months of therapy. Eight of 25 conducted trials were selected for review.
Meta-analysis of 6 homogeneous trials demonstrated a significant decrease in pulmonary artery pressure: —7 mm Hg (95% confidence interval, —3 to —11 mm Hg; P<.01). Heterogeneity of trial results appeared to be due to differences in the severity of initial pulmonary artery pressures and to differences in the dosage of nifedipine rather than the type of disease state.
Meta-analysis of the trials of nifedipine therapy in patients with pulmonary hypertension demonstrated a decrease in pulmonary artery pressure that was associated with an amelioration of clinical symptoms. Because of the paucity of data, however, larger trials are needed to better define its clinical value.Arch Intern Med. 1997;157:621-625
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 14
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.